Author

James E. Crowe

h-index 15 View on Semantic Scholar

We have 3 of 68 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

ACE2-like Catalytic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies

Many people are affected by difficult-to-understand clinical phenomena associated with acute SARS-CoV-2 infection and by post-acute sequelae of COVID-19 (PASC, or long COVID, LC). The mechanisms responsible for the clinical phenomena have not been well established. The host cell receptor for SARS-CoV-2 is human angiote...

Yu-Feng Song, Frances Mehl, Tom No et al. · Pathogens · 0 citations

Open access Sep 2026

Dengue virus 2 lacking N153 glycosylation displayed enhanced recognition by neutralizing antibodies

Deglycosylated (N153Q) dengue virus (DENV) mutant shows attenuated infection in a mouse model, mainly due to its increased antibody susceptibility. This is consistent with the neutralization assay showing human monoclonal antibodies 2D22 and C10 are more potent towards the mutant than the wild-type (WT) virus. Here,...

G. Fibriansah, T. Ng, X. Lim et al. · npj Viruses · 0 citations

Aug 2026

Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants

G germline revertant analysis of the COV2-3731 mAb provided additional insights into how this COV2-3731 and other IGHV3-53/3-66-encoded public antibodies evolve to gain breadth against antigenically distinct SARS-CoV-2 variants such as BA.2.3.2, BA.3.1, KP.2.2, and, to some extent, KP.3.3.2.

Naveenchandra Suryadevara, Seth J. Zost, John M. Powers et al. · bioRxiv · 0 citations